Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business ...

FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million –– Q4 2025 U.S. Net Product ...
Finanznachrichten

Esperion Therapeutics, Inc.: Esperion Reports Fourth Quarter and Full Year 2025 Financial ...

- FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million - - Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total ...
Le Lézard

Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary ...

Vertex Pharmaceuticals Incorporated today announced positive data from a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and ...